ABSTRACT HIV-and highly active antiretroviral therapy (HAART)-associated elevations in oxidative stress likely play a role in incomplete immune reconstitution, opportunistic infections and non-AIDS co-morbidities. We aimed to test the hypothesis that children living with HIV exhibit elevated markers of oxidative stress and reduced antioxidant profiles and that HAART-therapy will exacerbate these differences. HIV-positive HAART-naïve (n ¼ 50) and HAART-treated (n ¼ 50) and HIV-negative control (n ¼ 50) participants, 3-15 years of age, were recruited from Black Lion Hospital in Ethiopia. Serum malondialdehyde (MDA) and bilirubin were higher and vitamin C and zinc were lower in HAARTnaïve and HAART-treated compared with HIV-negative subjects and higher in HAART-treated compared with HAART-naïve subjects. Uric acid was higher in HAART-naïve compared with HAARTtreated and HIV-negative subjects. Differences in MDA and several antioxidants were also observed across treatment regimens. Thus, children living with HIV exhibited systemic elevations in oxidative stress and reduction in antioxidants, which are exacerbated with HAART therapy. 
(HAART) era, antioxidant micronutrient supplements were investigated as a potential therapy and showed success in delaying the progression of AIDS [9, 10] . People living with HIV taking HAART continue to exhibit systemic elevations in oxidative stress; however, results regarding the effectiveness of co-administration of antioxidant supplements with HAART on clinical outcomes remain mixed [8] [9] [10] [11] [12] [13] [14] [15] . Oxidative stress likely plays a central role in the incomplete immune reconstitution, risk of opportunistic infection and development and progression of non-AIDS-related co-morbidities. In the absence of a cure, pediatric HIV patients face life-long HAART treatment; parsing the milieu of factors associated with HIV-infection and HAART that mediate longterm viral suppression, while minimizing complications, is particularly critical children living with HIV.
The aim of this cross-sectional study was to test the hypothesis that children living with HIV will exhibit an elevation in markers of oxidative stress and reduction in antioxidants and that HAART therapy will exacerbate these changes. This article reports oxidative stress and antioxidant profiles in HIVnegative and HIV-positive HAART-naïve and HAART-treated pediatric subjects in Addis Ababa, Ethiopia.
M A T E R I A L S A N D M E T H O D S
This cross-sectional study was approved by the ethics and research review committee of the Department of Biochemistry (Protocol number 0019/2012) and Department of Pediatric and Child Health, Addis Ababa University and conducted during the period of July 2012 to March 2013 in Tikur Anbessa Specialized Teaching hospital (TASTH), Addis Ababa, Ethiopia. HAART-treated and HAART-naïve HIV-positive participants between 3 and 15 years of age were recruited sequentially from the TASTH Pediatric HIV Clinic. HIV-seronegative participants were recruited from the TASTH Pediatric outpatient clinic. Participants who were admitted for cancer, renal failure, liver disease, diabetes, heart disease and taking therapy for these diseases were excluded. Informed written consent was obtained from the parent or guardian of the 150 participants, composed of 50 HIV-positive HAART-naïve, 50 HIV-positive HAART-treated and 50 HIV-negative participants, before their enrolments in the study. Participants fasted for at least 8 h and 5 ml of venous blood was drawn and collected in EDTA tubes; after centrifugation, the serum was stored at À20 C until malondialdehyde (MDA), vitamin C, zinc, total and direct bilirubin, uric acid were analyzed. All data were expressed as mean 6 SD and the statistical significance was evaluated by one-way analysis of variance. Statistical significance across groups was evaluated by performing a Student's t-test and the MannWhitney U-test; p < 0.05 was considered statistically significant.
Laboratory analysis Vitamin C. Serum vitamin C was determined by highperformance liquid chromatography with a C 18 reversed phase column to elute with mobile phase and with ultraviolet detection (DDU-20 A5 model, SHIMADZU, Japan). Vitamin C was estimated from the standard curve with the area of each chromatogram.
Serum Zinc. Five-fold diluted serum samples were aspirated into the atomic absorption flame AA-6200 model (SHIMADUZ, Japan), by adjusting the atomic absorption working condition and the optical density of each diluted sample for zinc with 5% (v/ v) glycerol as a blank solution, absorption was observed at 213.9 nm wavelength.
Uric acid. Uric acid was quantified using an automated clinical chemistry analyzer (HmaStar 300, Germany) by means of H 2 O 2 formation by the action of uricase on uric acid, which causes oxidative coupling of 2-Hydroxy-3-5 Dichloro-benzenesulfonate (DHBS) and 4-aminoantipyrine in the presence of peroxidase, forming a red quinoneimine dye. The absorbance was measured at 520 nm.
Total and direct bilirubin. Bilirubin and the diazo reagent form an azobilirubin complex, which was measured colorimetrically. Conjugated bilirubin is water soluble and reacts with diazo reagent in a water solution, and un-conjugated bilirubin is not water soluble; alcohol was used to bring the unconjugated bilirubin into solution. The absorbance was read at 540 nm (Roche/Hitachi 902).
Albumin. Serum albumin was quantified using an automated clinical chemistry analyzer machine (HmaStar 300, Germany) by the bromocresol green (BCG) dye binding method. The intensity of the albumin-BCG complex formed when albumin binds with BCG in a suitable buffer (pH 4.2) was measured at 630 nm.
Malondialdehyde. Serum samples or standards were mixed with butylated hydroxytoluene reagent, orthophosphoric acid (0.2 M) and thiobarbituric acid. After incubation at 90 C for 45 min in a water bath, the tubes were placed on ice to stop the reaction, and thiobarbituric acid reactive substances were extracted once with 500 ml n-butanol; 250 ml of the upper butanol phase of each sample was placed into a flat-bottom 96-well plate and read at 540 nm. MDA equivalents were quantitatively calculated from calibration curve of MDA standards.
R E S U L T S
Demographic characterization HAART-naïve subjects were, on average, 1 year older than the HIV-negative and HAART-treated subjects. No differences in sex were present across groups. CD4 cell count and serum albumin were decreased in HIV-positive HAART-naïve and HIVpositive HAART-treated participants, compared with the HIV-negative control group and elevated in HAART-treated, compared with HAART-naïve participants (Table 1) .
Lipid peroxidation and altered antioxidant profiles with HIV and HAART HIV-positive HAART-naïve subjects exhibited elevated MDA, total and direct bilirubin and uric acid, and reduced vitamin C and zinc concentrations compared with HIV-negative subjects. HIV-positive HAART-treated subjects exhibited lower elevated MDA and total and direct bilirubin and reduced vitamin C and zinc concentrations compared with HIVnegative subjects. HIV-positive HAART-treated subjects exhibited elevated MDA, vitamin C and zinc and reduced total and direct bilirubin and uric acid concentrations compared with HIV-positive HAART-naïve subjects.
Lipid peroxidation and altered antioxidant profiles across HAART regimens Albumin levels were lower in participants taking D4T/ 3TC/NVP Stavudine (D4T)/Lamivudine (3TC)/ Nevirapine (NVP) and Zidovudine (AZT)/3TC/ NVP compared with those taking D4T/3TC/ Efavirenz (EFV), and lower in participants taking D4T/3TC/NVP and AZT/3TC/EFV (Table 2) . MDA levels were lower in participants who were taking D4T/3TC/NVP and AZT/3TC/EFV, compared with those taking AZT/3TC/NVP. These data also show a nominal increased MDA level in participants taking D4T/3TC/EFV, compared with those taking AZT/3TC/NVP, but this difference was not statistically significant (p ¼ 0.05). Serum vitamin C levels were lower in participants taking AZT/3TC/EFV and D4T/3TC/NVP compared with participants taking AZT/3TC/NVP and D4T/3TC/EFV. No differences were observed in zinc levels across treatment groups. Total bilirubin levels were lower in participants taking either EFV-containing regimen compared with those taking either NVP-containing regimen. Uric acid concentrations were lower in participants taking either D4T-containing regimen compared with those taking either AZT-containing regimen.
D I S C U S S I O N
In 2012, 34 million people, including 3.3 million children, were living with HIV, and there were 1.7 million AIDS-related death worldwide and 2.5 million new HIV infections, including 330 000 new infections in children [16] . Both HIV infection and HAART are associated with elevations in oxidative stress, which likely plays a key role in incomplete immune reconstitution, risk of opportunistic infections and non-AIDS-related co-morbidities; these complications are of particular concern in pediatric populations that face the potential for life-long therapy. The aim of this work was to assess markers of oxidative stress and antioxidant profiles in HIVseronegative, HIV-seropositive HAART-naïve and HIV-seropositive HAART-treated pediatric subjects in Addis Ababa, Ethiopia.
ROS with HIV infection and HAART
Several previous studies found that HIV-positive adult subjects show higher levels of oxidative stress, as indicated by increased serum lipid peroxidation, compared with healthy controls [17] [18] [19] [20] . Further, others have shown that oxidative stress is further elevated with HAART therapy in adult populations, compared with HIV-positive, HAART-naïve subjects [21] [22] [23] . The results of the current study support these previous findings, suggesting that HIV infection leads to elevated lipid peroxidation, which is further elevated by HAART therapy. Further, these results suggest that subjects taking D4T-containing regimens exhibited lower lipid peroxidation, compared with AZT/3TC/NVP.
Serum micronutrient antioxidants
Vitamin C is a powerful antioxidant; Allard et al. showed that vitamin C (1000 mg daily) and vitamin E (DL-a-tocopherol acetate, 800 IU daily) supplementation reduced lipid peroxidation in HIVpositive HAART-naïve subjects [15] . Zinc deficiency has been associated with decreases in CD4 counts, progression of AIDS and mortality in HIV-infected patients [24] . The current study suggests that HIV infection reduces vitamin C and zinc concentrations, which for most regimens are only partially restored by HAART. Previous literature supports the findings that zinc and vitamin C are significantly lower in HIV-positive HAART-naïve children, compared with HIV-negative controls [1, 25, 26] . The initiation of HAART improves serum zinc levels [24, 27] . Ndeezi et al. [27] showed an elevated prevalence of zinc deficiency in HIV-positive HAART-naïve, compared with HAART-treated, children. Bunupuradah et al. reported that higher pre-HAART levels of zinc were associated with better improvement in CD4 counts at 48 weeks post-HAART initiation [24] . Ngondi et al. showed a dependence in vitamin C with specific HAART regimen but, in contrast to our findings, they found lower levels of serum vitamin C in HAART-treated compared with HAART-naïve subjects [23] ; this may be because the HAART-treated group had a much lower CD4 cell count and much higher viral loads compared with the HAART-naïve group.
Serum levels of metabolite antioxidants
Uric acid is potent antioxidant and scavenger of ROS, contributes as much as two-thirds of all free radical scavenging capacity in human serum and serves as a protective physiological role by suppression of the Fenton reaction and prevention of lipid peroxidation [28] [29] [30] . The current study suggests that HIV infection leads to an increase in uric acid, which is restored following HAART. Both hypouricemia and hyperuricemia have been reported in HIV-positive HAART-naïve subjects [31, 32] . The literature supports the finding that uric acid levels are normalized following antiretroviral therapy [33, 34] , with the exception of subjects taking D4T-or didanosine-containing regimens, which may elevate uric acid levels [35] , a finding that our results support.
Bilirubin, an endogenous product of heme degradation, is a stronger antioxidant potential than a-tocopherol, attenuates hydrogen peroxide-induced endothelial leukocyte rolling, inhibits NADPH oxidase activity in vitro and serves as a potent lipid chain-breaking antioxidant under physiological conditions [36, 37] . The current study suggests that HIV infection increases total and direct serum bilirubin concentrations, which are partially reduced toward levels of HIV-negative subjects. Further, total bilirubin levels were higher in children taking NVPcontaining regimens compared with those taking EFV-containing regimens. The latter finding is supported by Metzger et al., who report that EFV monotherapy reduces bilirubin levels in HIV-negative healthy volunteers [38] , which may involve induction of uridine 5 -diphopho-glucurono-syltransferase 1A1 (UGT1A1), the enzyme responsible for hepatic conjugation of bilirubin, and bile efflux transporters [39] . Hyperbilirubinemia has been reported in adults and children taking the HIV protease inhibitor atazanavir, via inhibition of UGT1A1 [40, 41] . Indeed, this HIV antiretroviral drug, atazanavir, was shown to induce moderate hyperbilirubinemia and improve brachial artery endothelial-dependent vasodilation when administered to HIV-negative type-2 diabetes mellitus patients [42] ; however, in virologically suppressed, HIV-infected adults on stable HAART, neither total bilirubin nor atazanavir use was associated with improved endothelial function, inflammation or oxidative stress [43] .
This study has several limitations. The crosssectional design of this study does not allow for a causal relationship between specific antiretroviral drugs. Further, the sample size was determined to assess differences between HIV-seronegative, HIVseropositive HAART-naïve and HIV-seropositive HAART-treated groups; however, the small sample size for secondary analysis across specific HAART regimens limits the statistical resolution across regimens and the conclusions that can be made regarding specific HAART regimens. Also, we did not test for other infectious diseases (e.g. Hepatitis B virus [HBV]) or other inflammatory markers (e.g. C-reactive protein); thus, it is possible that there exists a recruitment bias owing to other opportunistic infections or other conditions (e.g. under-nutrition or malnutrition) across groups that is mediating the observed differences in oxidative stress.
C O N C L U S I O N HIV patients exhibit systemic elevations in oxidative stress, which are further elevated with HAART therapy and are associated with alterations in antioxidant profiles. Such alterations in oxidative stress may play a role in the incomplete immune reconstitution, risk of opportunistic infection and development and progression of non-AIDS-related co-morbidities. An urgent need remains to identify novel therapies that target the reduction of oxidative stress in children and adults living with HIV as potential strategies to reduce AIDS-and non-AIDS-related complications. 
